✦ LIBER ✦

Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant

✍ Scribed by Court Pedersen; Tiina Petaja; Gitte Strauss; Hans C. Rumke; Airi Poder; Jan Hendrik Richardus; Bart Spiessens; Dominique Descamps; Karin Hardt; Matti Lehtinen; Gary Dubin

Book ID: 116593441
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 583 KB
Volume: 40
Category: Article
ISSN: 1054-139X
DOI: 10.1016/j.jadohealth.2007.02.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunogenicity of a Prophylactic Quadriv

Immunogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescent Transplant Recipients

✍ Gomez-Lobo, V.; Moudgil, A.; Whyte, T.; Kaufman, S.; Torres, C.; Mete, M. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Impact of smoking on the quantity and qu

Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study

✍ Proscovia B Namujju,Emma Pajunen,Aline Simen-Kapeu,Lea Hedman… 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 275 KB

Induction of immune memory following adm

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

✍ Sven-Eric Olsson; Luisa L. Villa; Ronaldo L.R. Costa; Carlos A. Petta; Rosires P 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 442 KB

Safety, immunogenicity, and efficacy of

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women

✍ Gonzalo Perez; Eduardo Lazcano-Ponce; Mauricio Hernandez-Avila; Patricia J. Garc 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 103 KB

## Abstract The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has been shown to be 95–100% effective in preventing HPV 6/11/16/18‐related cervical and genital disease in women naï

Comparison of the Immunogenicity and Rea

Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women

✍ Block, S. L.; Nolan, T.; Sattler, C.; Barr, E.; Giacoletti, K. E.D.; Marchant, C 📂 Article 📅 2006 🏛 American Academy of Pediatrics 🌐 English ⚖ 409 KB

Efficacy of a bivalent L1 virus-like par

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

✍ Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins 📂 Article 📅 2004 🏛 The Lancet 🌐 English ⚖ 185 KB